Evidence map›Paper›PMID 35213534›Full record

ArticlePLoS computational biology2022

Causal reasoning over knowledge graphs leveraging drug-perturbed and disease-specific transcriptomic signatures for drug discovery.

Daniel Domingo-Fernández, Yojana Gadiya, Abhishek Patel, Sarah Mubeen, Daniel Rivas-Barragan, Chris W Diana, Biswapriya B Misra, David Healey, Joe Rokicki, Viswa Colluru

Open access · goldAbstract read
In one paragraph

Article in PLoS computational biology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.4field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 17 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 3 countries.

Daniel Domingo-FernándezEnveda Biosciences, Boulder, Colorado, United States of America.ORCID 0000-0002-2046-6145
Yojana GadiyaEnveda Biosciences, Boulder, Colorado, United States of America.ORCID 0000-0002-7683-0452
Abhishek PatelEnveda Biosciences, Boulder, Colorado, United States of America.
Sarah MubeenBonn-Aachen International Center for IT, Rheinische Friedrich-Wilhelms-Universität Bonn, Bonn, Germany.ORCID 0000-0002-9858-3755
Daniel Rivas-BarraganBarcelona Supercomputing Center, Barcelona, Spain.ORCID 0000-0003-0163-7890
Chris W DianaEnveda Biosciences, Boulder, Colorado, United States of America.ORCID 0000-0002-1864-8150
Biswapriya B MisraEnveda Biosciences, Boulder, Colorado, United States of America.ORCID 0000-0003-2589-6539
David HealeyEnveda Biosciences, Boulder, Colorado, United States of America.ORCID 0000-0002-9584-9757
Joe RokickiEnveda Biosciences, Boulder, Colorado, United States of America.ORCID 0000-0002-8255-0828
Viswa ColluruEnveda Biosciences, Boulder, Colorado, United States of America.ORCID 0000-0002-6208-9288
Enveda Therapeutics (United States) · USBarcelona Supercomputing Center · ESUniversity of Bonn · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Network-based approaches are becoming increasingly popular for drug discovery as they provide a systems-level overview of the mechanisms underlying disease pathophysiology. They have demonstrated significant early promise over other methods of biological data representation, such as in target discovery, side effect prediction and drug repurposing. In parallel, an explosion of -omics data for the deep characterization of biological systems routinely uncovers molecular signatures of disease for similar applications. Here, we present RPath, a novel algorithm that prioritizes drugs for a given disease by reasoning over causal paths in a knowledge graph (KG), guided by both drug-perturbed as well as disease-specific transcriptomic signatures. First, our approach identifies the causal paths that connect a drug to a particular disease. Next, it reasons over these paths to identify those that correlate with the transcriptional signatures observed in a drug-perturbation experiment, and anti-correlate to signatures observed in the disease of interest. The paths which match this signature profile are then proposed to represent the mechanism of action of the drug. We demonstrate how RPath consistently prioritizes clinically investigated drug-disease pairs on multiple datasets and KGs, achieving better performance over other similar methodologies. Furthermore, we present two case studies showing how one can deconvolute the predictions made by RPath as well as predict novel targets.

Indexed as

Pattern Recognition, AutomatedTranscriptomeAlgorithmsDrug DiscoveryDrug Repositioning

Identifiers

PMID35213534
PMCPMC8906585
OpenAlexW4221048327

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.